B
Breanne Donohue
Researcher at Novartis
Publications - 4
Citations - 669
Breanne Donohue is an academic researcher from Novartis. The author has contributed to research in topics: Medicine & Adverse effect. The author has an hindex of 2, co-authored 3 publications receiving 542 citations.
Papers
More filters
Journal ArticleDOI
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Andreas Hochhaus,Giuseppe Saglio,Timothy P. Hughes,Richard A. Larson,Dong-Kee Kim,Surapol Issaragrisil,P. le Coutre,Gabriel Etienne,Pedro Enrique Dorlhiac-Llacer,Richard E. Clark,Ian W. Flinn,Hirohisa Nakamae,Breanne Donohue,Weiping Deng,Darshan Dalal,Hans D. Menssen,Hagop M. Kantarjian +16 more
TL;DR: Long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP, and few deaths in any arm were associated with CVEs, infections or pulmonary diseases.
Journal ArticleDOI
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd
Richard A. Larson,Dong-Wook Kim,Surapol Issaragrilsil,Philipp le Coutre,Pedro Enrique Dorlhiac Llacer,Gabriel Etienne,Richard E. Clark,Ian W. Flinn,Hirohisa Nakamae,Andreas Hochhaus,Giuseppe Saglio,Hagop M. Kantarjian,Breanne Donohue,Weiping Deng,Hans D. Menssen,Timothy P. Hughes +15 more
TL;DR: NIL resulted in better MR vs IM across all Sokal risk groups, including higher rates of EMR and MR4.5 by 5 y, and is unlikely to change with longer f/u because, among pts without MMR by 5Y, few remained on core treatment at data cutoff.
Journal ArticleDOI
A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.
Ahmar U. Zaidi,Alexander K. Glaros,Alexander K. Glaros,Soyon Lee,Taiji Wang,Rhea Bhojwani,Eric Morris,Breanne Donohue,Jincy Paulose,Şerban R. Iorga,Dave Nellesen +10 more
TL;DR: In this article, a systematic literature review was conducted to identify literature describing the frequency of vaso-occlusive crises experienced by individuals with Sickle cell disease in real-world settings.
Journal ArticleDOI
S108: a systematic post-marketing (pm) review of rare infusion-related reactions (irrs) presenting as pain events during or after crizanlizumab infusion in patients with sickle cell disease (scd)
Julie Kanter,A. Shah,Varoon Joshi,Harshit S Mehta,M. Levine,Uma Arunagiri,Jincy Paulose,Breanne Donohue,Antonella Scalera,Deepa Manwani +9 more
TL;DR: Kang et al. as mentioned in this paper reviewed PM data on IRRs presenting as pain events in SCD patients treated with crizanlizumab and found that most patients experienced back pain, pain in extremity, arthralgia, musculoskeletal chest pain and headache.